Neola Medical AB (NEOLA) Fair Value & Analysis
Healthcare · SE · Market cap 54.9M SEK (≈ $5.7M) · ISIN SE0014829255
Risks
Fair value as of: Aug 18, 2026
From 1 valuation models · updated 13 days ago
Share price −18.0% over the past month.
Below-average quality, and trading another 173% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 0.2200). The favourable scenario is already priced in.
- Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.1200 to kr 0.2200) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.
How to read this chart
60‑month range kr 0.4800 – kr 3.71 · fair‑value band kr 0.1200 – kr 0.2200 · the kr 0.4920 price screens above the kr 0.1800 fair value. Dashed = 300-day average. As of Aug 18, 2026.
Analysis
Neola Medical AB (NEOLA) currently trades at kr 0.4920, while our model-based Fair Value estimate is kr 0.1800, implying the stock looks roughly 63.4% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 9.0M SEK. Revenue grew 32.6% year over year. It earns a return on equity of -15.3%. The balance sheet holds a net cash position of 16.1M SEK. Fundamentals as of Aug 18, 2026
Our scenario range runs from kr 0.1200 (bear case) to kr 0.2200 (bull case); at kr 0.4920, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at -63%, NEOLA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when NEOLA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 3
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden.
Full company description
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Neola Medical AB reported revenue of kr 0 in FY2025 versus kr 625K in FY2021. Reported net income was −kr 11.0M in FY2025.
NEOLA screens 173% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 363 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | -34% |
| Stryker Corporation SYK | $322.12 | $186.28 | -42% |
| Medtronic plc MDT | $89.97 | $65.57 | -27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | -34% |
| Edwards Lifesciences Corporation EW | $90.78 | $41.02 | -55% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | -14% |
| DexCom, Inc DXCM | $88.96 | $38.95 | -56% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | -14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | -39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
Compare Neola Medical AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Neola Medical AB (NEOLA) overvalued or undervalued?
What is the fair value of NEOLA?
What is the quality score of NEOLA?
What is the revenue of Neola Medical AB (NEOLA)?
What is the net profit margin of NEOLA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Neola Medical AB in the live analysis
One click puts Neola Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.